Skip to main navigation Skip to search Skip to main content

Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors

  • G Kate Park
  • , Jeong Heon Lee
  • , Eduardo Soriano
  • , Myunghwan Choi
  • , Kai Bao
  • , Wataru Katagiri
  • , Do-Yeon Kim
  • , Ji-Hye Paik
  • , Seok-Hyun Yun
  • , John V Frangioni
  • , Thomas E Clancy
  • , Satoshi Kashiwagi
  • , Maged Henary
  • , Hak Soo Choi
  • Massachusetts General Hospital and Harvard Medical School
  • Georgia State University
  • Department of Pathology and Laboratory Medicine
  • Weill Cornell Medical College in Qatar
  • Curadel
  • Brigham and Women's Hospital and Dana-Farber Cancer Institute

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Design of tissue-specific contrast agents to delineate tumors from background tissues is a major unmet clinical need for ultimate surgical interventions. Bioconjugation of fluorophore(s) to a ligand has been mainly used to target overexpressed receptors on tumors. However, the size of the final targeted ligand can be large, >20 kDa, and cannot readily cross the microvasculature to meet the specific tissue, resulting in low targetability with a high background. Here, we report a small and hydrophilic phenoxazine with high targetability and retention to pancreatic neuroendocrine tumor. This bioengineered fluorophore permits sensitive detection of ultrasmall (<0.5 mm) ectopic tumors within a few seconds after a single bolus injection, highlighting every tumor in the pancreas from the surrounding healthy tissues with reasonable half-life. The knowledge-based approach and validation used to develop structure-inherent tumor-targeted fluorophores have a tremendous potential to improve treatment outcome by providing definite tumor margins for image-guided surgery.

Original languageEnglish
Pages (from-to)101006
JournaliScience
Volume23
Issue number4
DOIs
StatePublished - 24 Apr 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors'. Together they form a unique fingerprint.

Cite this